Nicole Léger and Jérôme Depaquit emphasise “the importance of preventing an extension of this anthroponotic species in Europe”,1 a point also stressed by Dujardin et al.,2 since leishmaniasis is not placed under public health surveillance in Europe.

We certainly agree with the authors that the indigenous transmission of *Leishmania donovani* to Cyprus needs to be proven, since the possibility of the invasion of Cyprus by anthropophilic *L donovani* vectors cannot a priori be excluded—particularly if we consider the geopolitical status of the island (figure, A). In this scenario, imported *L donovani*-infected sandflies would need either to transmit the parasite within their short lifespan or survive and spread. While the first hypothesis is contradicted by the 2–3 year observed infection period, the second is possible if the Cypriot ecosystem/microclimate is taken into account (figure, B). However, the five reported human cases,3 including an additional cutaneous leishmaniasis case in Nicosia (unpublished), were found in three of the five prefectures of the government-controlled area. Each prefecture belongs to a distinct, relatively distant, biogeographical region (figure, B). Within the context of sandflies’ weak flight, there is little chance of even a small number of infected sandflies having traveled and spread to these different locations.

This raises the question of whether the Cyprus sandfly fauna, present since the Miocene period,4 can transmit *L donovani*. This fauna is comprised of nine closely related species of the Phlebotominae subfamily (*Phlebotomus* and *Sergentomyia* genera), which are proven or probable vectors of Mediterranean canine visceral leishmaniasis (CVL) caused by *L infantum*. *P neglectus*, a species with a wide distribution in eastern Mediterranean countries, was only recently identified in the northern non-government-controlled area of Cyprus.5 Interestingly, the *Larroussius* species *P galilaeus* and *P tobbi*, are the most abundant in both the government-controlled and northern areas of Cyprus.6,7 Notably, *P tobbi*, a broadly permissive vector, has been found in high dog seropositivity areas during several field surveys. As a result it is considered to be the vector of *L infantum* in Cyprus,8,9 and this is also the case in the eastern Mediterranean region (figure, A). Léger and Depaquit question the role of *P tobbi* as a vector of *L donovani* in Cyprus based simply on their observation that, unlike in the north, no human leishmaniasis cases were reported in the southern part of the island.1 However, in Turkey, it was recently shown through blood-meal identification that *P tobbi* feeds preferentially on cattle and people.10 If we also consider the few reported cases due to *L infantum*,11 and the identification of both species in a dog,3 the trophic preferences of local populations of *P tobbi* remain to be established. In addition, the host immune response depends, not only on whether sandflies are infected, but also on their parasite load.12 Pre-exposure to certain sandfly saliva components could affect immune response to *Leishmania* spp infection, and consequently disease outcome.13 Therefore we consider that the conclusion reached, concerning the lack of anthropophily of *P tobbi* in Cyprus1 may be illusive and

---

**Figure:** Regional distribution of three putative Phlebotomus spp vectors (A) and locations of the human *L donovani* cases in Cyprus (B)
that \textit{P. tobbi} could be incriminated for the transmission of both \textit{L. infantum} and \textit{L. donovani}.

Other candidate vectors of \textit{L. donovani} MON-37 could be \textit{P. gallaeus}\textsuperscript{1} and also \textit{P. economides} and \textit{P. alexandri}, which are more abundant in Paphos and Limassol prefectures\textsuperscript{4} where the human cases were detected. Notably, \textit{P. alexandri} is considered the proven vector of \textit{L. donovani} and \textit{L. infantum} in China\textsuperscript{14} and Iran,\textsuperscript{15} respectively, and is also found in regions where \textit{L. donovani} MON-37 is present.\textsuperscript{1}

Therefore, the most probable scenario is that of importation and settlement of \textit{L. donovani} MON-37 in Cyprus through infected individuals from \textit{L. donovani} MON-37 endemic countries, including both legal and illegal laborers which most probably played or still play the part of parasite reservoir. Population genetic analysis of the \textit{L. donovani} MON-37 strains from Cyprus, including those from other endemic countries, will give answers to the questions addressed above. Investigation of human exposure to the different sandfly species present in Cyprus and of sandfly blood meal preferences, as well as experimental transmission by their bite, will help assess their ability to act as experimental transmission by their bite, will help assess their ability to act as vectors. These actions aim to identify the responsible vector(s) among the putative candidates and access the risk/danger of anthroponotic Leishmania species spread in Europe.

\textbf{Maria Antoniou, Christos Haralambous, Apostolos Mazeris, Francine PratLong, Jean-Pierre Dedet, Ketty Soteriadou}\textsuperscript{*}

\textbf{Laboratory of Clinical Bacteriology, Parasitology, Zoonoses, and Geographical Medicine, University of Crete, Crete, Greece (MA); Laboratory of Molecular Parasitology, Hellenic Pasteur Institute, Athens, Greece (CH, KS); Veterinary Services of Cyprus, Nicosia, Cyprus (AM); Université Montpellier 1 et Centre Hospitalier Universitaire de Montpellier, Laboratoire de Parasitologie et Centre National de Reference des Leishmaniasis, Montpellier, France (FP, J-PD)}

ksoteriadou@pasteur.fr

We declare that we have no conflict of interest. This work was partly supported by the Research Promotion Foundation in Cyprus (HEALTH/0102/04), the Hellenic Pasteur Institute, and EU (LeishMed consortium FP6-2002-INCO-MPC-1 and EDEN, http://www.eden-fp6project.net/). The study sponsors had no role in study design, data interpretation, or in the writing of the report. We thank L Gradoni and K Nicolaides for constructive discussions and critical suggestions.


\textbf{Vaccine immunogenicity in injecting drug users}\textsuperscript{2}

\textbf{Stefan Baral and colleagues published an interesting review on vaccination and injecting drug users in October 2007.\textsuperscript{7}} The authors argued that detectable hepatitis B virus (HBV) surface antigen specific antibodies (antiHBs) may not be the best measure of immunity to hepatitis B following vaccination.\textsuperscript{1} The authors went on to quote the results of an Italian prospective cohort study by Lugoboni et al.\textsuperscript{2} Baral et al claimed that the study showed that none of the 258 patients who received three or more doses of vaccine went on to contract hepatitis B, despite a seroprevalence of protective antiHBs of only 71.9%.\textsuperscript{1} This is not correct, since the study actually reported that two vaccinated patients developed hepatitis B (as measured by the detection of antibody to HBV core antigen (antiHBC)). One patient had received two doses of vaccine, while the other had received three doses. This was out of the 258 patients who were followed up. The article did not state that this group received three or more vaccinations. In fact, the article suggests (but does not explicitly state) that this